Tesamorelin: which fat changed, and what does it mean?

Tesamorelin can reduce excess deep abdominal fat in the specific medical setting of HIV-associated lipodystrophy. That is different from general weight loss. Its US EGRIFTA WR label describes a weight-neutral effect and says it is not indicated for weight-loss management. Smaller studies also found reductions in liver fat in people with HIV, but a smaller fat measurement does not by itself prove fewer heart attacks, reversal of liver scarring or a lasting result after treatment ends. Current WR label; Liver-fat trial.

“Belly fat” can mean different things

Tesamorelin is an analogue of growth-hormone-releasing hormone: it stimulates the body's release of growth hormone. The interest in it comes from measured changes in particular fat compartments, rather than evidence that increasing growth hormone is generally beneficial. HIV-associated lipodystrophy can involve changes in fat distribution; it is not simply another name for having a higher body weight. The labeled use concerns excess abdominal fat in adults with that condition. WR indication and pharmacology.

Liver fat is a different readout again

Liver fat refers to fat stored within the liver. The 2014 study measured a liver lipid-to-water ratio using magnetic resonance spectroscopy and reported a modest reduction. A later 12-month randomized trial specifically enrolled people with HIV and fatty liver, using hepatic fat fraction as its primary outcome. These related measurements should not be pooled as though every percentage uses the same denominator. 2014 study; 2019 liver-fat trial.

People and analysis

The full 2019 manuscript reports 61 randomized. The primary analysis used available follow-up imaging from 26 tesamorelin and 28 placebo participants.

Measured finding

The estimated liver-fat difference was −4.1 percentage points versus placebo at 12 months (95% CI, −7.6 to −0.7), also reported as a 37% relative reduction.

Interpretation

Those are two ways to express a liver-fat result, not a 37% reduction in body weight or total body fat.

Less liver fat did not establish reversal of existing liver scarring. Fibrosis progression was a secondary finding: two of 19 participants with evaluable biopsies progressed in the tesamorelin group, compared with nine of 24 with placebo (P=0.04). But existing fibrosis improved in two versus three participants, without a significant difference (P=0.71). Overall liver-disease activity, inflammation and ballooning-cell scores also did not significantly improve across the whole cohort. These small biopsy comparisons do not establish prevention of cirrhosis, liver failure or death. Original histology results and limitations.

The 2024 integrase-inhibitor report analyzes a subgroup of that same trial. Of 38 taking those HIV medicines at baseline, 31 completed the 12-month study. It found reductions in visceral and liver fat, but no significant body-mass-index or subcutaneous-fat change. It adds information about that treatment context; it is not an independent repeat in a new population or proof of benefit for everyone with medication-associated weight gain. Original subgroup analysis.

The approved WR indication does not become a general fatty-liver indication because a research study found a liver-fat change. The current label and the actual study population answer separate questions. Likewise, the FDA's original 2010 approval memorandum explains why reduced visceral fat did not establish cardiovascular benefit; the current WR label still says long-term cardiovascular safety has not been established. Historical FDA approval rationale; Current label.

Does reduced visceral fat stay reduced after stopping?

The current WR label reports extension phases of trials using an earlier EGRIFTA formulation. People who completed 26 weeks of active treatment were re-randomized to continue it or switch to placebo for another 26 weeks. This helps distinguish an on-treatment effect from a permanent change; it is not a schedule or recommendation for starting or stopping treatment.

1. Initial phase: participants received active treatment for weeks 0–26.
2. New comparison: in Study 2's extension, 92 completers were assigned to continue treatment and 85 to switch to placebo.
3. Weeks 26–52: the label reports modeled mean visceral-fat changes of −5% with continuation and +16% after switching to placebo, relative to the week-26 measurement.

Week 26 is the reference point for those percentages. They do not mean a 16-percentage-point increase in total body fat, or that every participant regained all lost fat. The label's analysis used last observation carried forward for missing values, and the extension population consisted of earlier treatment completers. The result supports caution about promises of permanent fat loss after a course; it does not predict what will happen to a particular person. WR clinical studies, extension phase and Table 4.

What risks and label cautions matter?

Tesamorelin increases growth hormone and IGF-1, a growth factor. The WR label warns that the effects of prolonged IGF-1 elevation are unknown. It also warns about glucose intolerance or diabetes, fluid retention and associated joint discomfort or carpal-tunnel symptoms, hypersensitivity reactions, and injection-site reactions. The label lists active malignancy, certain disruptions of the hypothalamic-pituitary system, known hypersensitivity and pregnancy among its contraindications. These are reasons for individual clinical assessment, not a monitoring or self-treatment checklist. WR contraindications and warnings.

A small study's reassuring average glucose result cannot erase that label warning. In the 2014 trial, fasting glucose rose more with tesamorelin early in treatment; the overall six-month glucose differences were not significant, while the HbA1c change was slightly greater. The 2019 study did not find a significant between-group glucose effect, but two participants receiving tesamorelin discontinued for high blood sugar (hyperglycemia); one had diabetes at baseline. More participants receiving tesamorelin also reported localized injection-site complaints. These findings belong to their selected populations and follow-up periods; they do not establish risk-free long-term use. 2014 metabolic results; 2019 safety results.

How to check a tesamorelin result

Ask four questions before carrying a number into a benefit claim: Which compartment? Which measurement? Which people and timepoint? Which actual health outcome? A visceral scan area, liver fat fraction, scale weight and a heart attack are different endpoints. Keep the result with the source that measured it.

If the claim omits the population, formulation, measurement or comparison, leave that inference unverified. Research in people with HIV does not establish the same result in an otherwise healthy person, and a short hormone experiment cannot fill in missing long-term clinical outcomes. A clinician can discuss the actual condition, established options and the applicable product label; this guide provides no dosing, administration, purchase or treatment plan.

Return to the tesamorelin profile or the off-label/preparation context and additional documents. The peptide topic guide keeps other compounds' evidence separate.

Selected-source and editorial check: November 10, 2026. The named original full reports, current product labeling and historical FDA memorandum were read. Separate supplementary files were not independently verified; no supplementary-only result is relied on. This is not a complete literature review, clinician approval or a claim of benefit for every formulation, population or purpose.